Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study
Adèle de Masson, M. Beylot‐Barry, C. Ram‐Wolff, Jean-Baptiste Méar, Stéphane Dalle, Jacques Rouanet, Saskia Ingen-Housz-Oro, Corentin Orvain, Julie Abraham, O. Dereure, Amandine Charbonnier, Jérôme Cornillon, Christine Longvert, Stéphane Barète, S. Boulinguez, E. Wierzbicka-Hainaut, F. Aubin, Marie‐Thérèse Rubio, Marc Bernard, Aline Schmidt-Tanguy, Roch Houot, Anne Pham‐Ledard, David Michonneau, Hélène Labussière‐Wallet, Jean-David Bouaziz, Florent Grange, Hélène Moins‐Teisserenc, Katayoun Jondeau, Samia Mourah, Maxime Battistella, Étienne Daguindau, Michaël Loschi, Alexandra Picard, Nathalie Franck, Natacha Maillard, Anne Huynh, Stéphanie Nguyen, Ambroise Marçais, G. Chaby, Patrice Céballos, Yannick Le Corre, Sébastien Maury, Jacques-Olivier Bay, H. Adamski, Emmanuel Bachy, Édouard Forcade, Gérard Socié, M. Bagot, Sylvie Chevret, Régis Peffault de Latour, on behalf of CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire, Pauline Brice, Laurence Michel
Abstract
Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.